2796 Pharmarise Holdings Corporation - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

2796

TSE Standard

Pharmarise Holdings Corporation

520

JPY

-2

(-0.38%)

Jan 29, 3:30 pm JST

3.39

USD

Jan 29, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
May, 2022	51,608	1,520	1,517	447	48.0	14	Jul 8, 2022	J-GAAP
May, 2023	52,030	1,438	1,431	333	35.5	14	Jul 11, 2023	J-GAAP
May, 2024	54,466	916	833	-351	-33.4	20	Jun 28, 2024	J-GAAP
May, 2025	63,508	293	136	-367	-32.5	14	Jun 25, 2025	J-GAAP
May, 2026 Guidance	66,795	1,123	941	266	23.1	14	Jun 25, 2025	J-GAAP
YoY	+5.2%	+283.3%	+591.9%	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
May, 2021	Jul 15, 2020	54,041	1,167	1,112	376	14	J-GAAP
	Jan 14, 2021	51,927	1,187	1,172	378	14	J-GAAP
Results	Jul 15, 2021	52,324	1,246	1,288	426	14	J-GAAP
May, 2022	Jul 15, 2021	Available in future release
Results	Jul 8, 2022
May, 2023	Jul 8, 2022
	Dec 29, 2022
Results	Jul 11, 2023
May, 2024	Jul 11, 2023
	Mar 25, 2024
	Jun 14, 2024
Results	Jun 28, 2024
May, 2025	Jun 28, 2024
	Dec 25, 2024
Results	Jun 25, 2025
May, 2026	Jun 25, 2025	66,795	1,123	941	266	14	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
May, 2002	8,706	－	Available in future release
May, 2003	9,803	+12.6
May, 2004	10,884	+11.0
May, 2005	13,187	+21.2
May, 2006	14,590	+10.6
May, 2007	15,395	+5.5
May, 2008	18,506	+20.2
May, 2009	19,994	+8.0
May, 2010	23,416	+17.1
May, 2011	26,825	+14.6
May, 2012	29,607	+10.4
May, 2013	33,357	+12.7
May, 2014	38,221	+14.6
May, 2015	39,506	+3.4
May, 2016	48,511	+22.8
May, 2017	52,949	+9.1
May, 2018	54,562	+3.0
May, 2019	51,728	-5.2
May, 2020	51,030	-1.3
May, 2021	52,324	+2.5
May, 2022	51,608	-1.4
May, 2023	52,030	+0.8
May, 2024	54,466	+4.7
May, 2025	63,508	+16.6
May, 2026 Guidance	66,795	+5.2	1,123	+283.3	941	+591.9	23.1	－

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
May, 2024	54,466	916	1.68	-5.08	-1.33	2.06	-33.4
May, 2025	63,508	293	0.46	-5.31	-1.20	2.07	-32.5
May, 2026 Guidance	66,795	1,123	1.68	4.03	0.89	2.23	23.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	63,508	1,657	1,517	958	127.7
Fiscal Year	May, 2025	May, 2012	May, 2022	May, 2013	May, 2013

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec - May, 2022	26,285	865	865	261	27.8	14	Jul 11, 2023	J-GAAP
Dec - May, 2023	27,518	206	132	-624	-59.4	20	Jun 28, 2024	J-GAAP
Dec - May, 2024	32,964	193	107	-254	-22.5	14	Jun 25, 2025	J-GAAP
Dec - May, 2025 Guidance	33,193	724	613	155	13.5	14	Dec 25, 2025	J-GAAP
YoY	+0.7%	+275.1%	+472.9%	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
May, 2023	1,438	1,817	2,520	-703	-1,072	4,734	20.21	J-GAAP
May, 2024	916	-406	2,714	-3,120	2,771	7,100	24.08	J-GAAP
May, 2025	293	-3,151	1,311	-4,462	939	4,891	15.32	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jun - Nov, 2023	26,948	710	701	273	28.3	84.2	Dec 25, 2023	J-GAAP
Jun - Nov, 2024	30,544	100	29	-113	-10.1	21.3	Dec 25, 2024	J-GAAP
Jun - Nov, 2025	33,602	399	328	111	9.8	34.9	Dec 25, 2025	J-GAAP
YoY	+10.0%	+299.0%	+1,031.0%	－	－

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Dec - Feb, 2023	13,726	153	98	-96	-9.3	1.1	Mar 25, 2024	J-GAAP
Mar - May, 2024	13,792	53	34	-528	-50.3	0.4	Jun 28, 2024	J-GAAP
Jun - Aug, 2024	15,231	52	23	-131	-11.7	0.3	Sep 25, 2024	J-GAAP
Sep - Nov, 2024	15,313	48	6	18	1.6	0.3	Dec 25, 2024	J-GAAP
Dec - Feb, 2024	16,035	-5	-47	-159	-14.1	0.0	Mar 25, 2025	J-GAAP
Mar - May, 2025	16,929	198	154	-95	-8.4	1.2	Jun 25, 2025	J-GAAP
Jun - Aug, 2025	16,753	152	115	-18	-1.6	0.9	Sep 25, 2025	J-GAAP
Sep - Nov, 2025	16,849	247	213	129	11.3	1.5	Dec 25, 2025	J-GAAP
YoY	+10.0%	+414.6%	+3,450.0%	+616.7%	+603.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec - Feb, 2020	12,793	-0.3	Available in future release
Mar - May, 2021	13,865	+11.5
Jun - Aug, 2021	13,062	+1.4
Sep - Nov, 2021	12,841	+0.4
Dec - Feb, 2021	12,676	-0.9
Mar - May, 2022	13,029	-6.0
Jun - Aug, 2022	12,861	-1.5
Sep - Nov, 2022	12,884	+0.3
Dec - Feb, 2022	12,985	+2.4
Mar - May, 2023	13,300	+2.1
Jun - Aug, 2023	13,471	+4.7
Sep - Nov, 2023	13,477	+4.6
Dec - Feb, 2023	13,726	+5.7
Mar - May, 2024	13,792	+3.7
Jun - Aug, 2024	15,231	+13.1
Sep - Nov, 2024	15,313	+13.6
Dec - Feb, 2024	16,035	+16.8
Mar - May, 2025	16,929	+22.7
Jun - Aug, 2025	16,753	+10.0
Sep - Nov, 2025	16,849	+10.0	247	+414.6	213	+3,450.0	11.3	+606.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	16,929	542	676	572	72.2
Fiscal Year	May, 2025	May, 2023	May, 2021	Nov, 2015	Nov, 2012

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
May, 2023	708.01	28.5	23,421	6,673	4,014	1.37	Jul 11, 2023	J-GAAP
May, 2024	636.25	24.3	29,486	7,153	3,530	1.78	Jun 28, 2024	J-GAAP
May, 2025	586.21	20.9	31,924	6,659	2,938	2.06	Jun 25, 2025	J-GAAP
Jun - Nov, 2025	ー	22.1	29,956	6,606	2,890	1.87	Dec 25, 2025	J-GAAP

Pharmarise Holdings Corporation(2796) Financial Results